폐 및 전립선의 신경 내분비 암종 환자에서 177lu-dtpa-sc16.56의 연구
폐 및 전립선의 고급 신경 내분비 암종에서 DLL3- 표적제의 뇌성 잠재력을 특성화
The purpose of this study is to find out whether 177Lu-DTPA-SC16.56 is a safe treatment for people with small-cell lung cancer or neuroendocrine prostate cancer
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Lisa Bodei, MD, PhD
- 전화번호: 212-639-7373
- 이메일: bodeil@mskcc.org
연구 연락처 백업
- 이름: Michael Morris, MD
- 전화번호: 646-422-4471
- 이메일: morrism@mskcc.org
연구 장소
-
-
New Jersey
-
Basking Ridge, New Jersey, 미국, 07920
- Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities)
-
연락하다:
- Lisa Bodei, MD, PhD
- 전화번호: 212-639-7373
-
Middletown, New Jersey, 미국, 07748
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
-
연락하다:
- Lisa Bodei, MD, PhD
- 전화번호: 212-639-7373
-
Montvale, New Jersey, 미국, 07645
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)
-
연락하다:
- Lisa Bodei, MD, PhD
- 전화번호: 212-639-7373
-
-
New York
-
Commack, New York, 미국, 11725
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities )
-
연락하다:
- Lisa Bodei, MD, PhD
- 전화번호: 212-639-7373
-
Harrison, New York, 미국, 10604
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)
-
연락하다:
- Lisa Bodei, MD, PhD
- 전화번호: 212-639-7373
-
New York, New York, 미국, 10065
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
수석 연구원:
- Lisa Bodei, MD
-
연락하다:
- Lisa Bodei, MD, PhD
- 전화번호: 212-639-7373
-
Rockville Centre, New York, 미국, 11553
- Memorial Sloan Kettering Nassau (Limited protocol activities)
-
연락하다:
- Lisa Bodei, MD, PhD
- 전화번호: 212-639-7373
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Subjects with histologically proven progressive metastatic high-grade neuroendocrine carcinomas of the lung (small-cell lung cancer) and prostate (neuroendocrine prostate cancer) that has relapsed following at least 1 line of standard chemotherapy i. Prostate cancer patients will be defined by either of the following criteria: ii. The presence of chromogranin staining on tissue iii. At least two of the pathogenic mutations of PTEN, RB1, or p53 iv. Disease exclusively involving the viscera v. Disease in which the PSA is <10 but the number of bone lesions is >20 vi. Histologic evidence of small cell carcinoma or other stains consistent with neuroendocrine disease (on the primary disease or metastases) vii. DLL3 positivity on previously available tissue specimens
-
Ability to understand and willingness to sign a written informed consent document
-
Aged 18 years or older at the time of signing consent
-
Progression of disease defined by one of the following occurring within 3 months of study entry:
i. At least a 20% increase in radiologically or clinically measurable disease; ii. Appearance of any new lesion; iii. For prostate cancer patients progression criteria will be per PCWG3: iv. Either v. A rising PSA over a sequence of at least 1-week intervals OR i. An increase in soft tissue disease to qualify for disease progression by RECIST 1.1 OR ii. Two new bone lesions by bone scintigraphy
Patients with metastatic disease by virtue of disease exclusively evident by PSMA PET will not be eligible. All patients must have metastatic disease by evidence of standard scintigraphic or anatomic imaging in accord with PCWG3
-
At least one tumor lesion on CT or MR ≥ 2 cm
-
ECOG performance status 0 to 2
-
Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.
-
Previous chemotherapy, immunotherapy, and/or investigational agents are allowed if completed ≥4 weeks prior to study entry. For patients who received systemic therapy prior to study entry, there must be documented progression of measurable disease since receiving systemic therapy prior to study entry.
-
Preserved hematological function:
i. Hb ≥9.0 g/dL; ii. WBC ≥3000/mm3; iii. ANC≥1500/mm3; iv. Platelets ≥75.000/mm3
-
Preserved renal function:
i. Serum creatinine ≤1.7 mg/dL ii. Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73m2
-
Preserved hepatic function:
i. aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x upper limit of normal (ULN) or ≤ 5 x ULN if liver metastases are present ii. bilirubin ≤ 1.5 x ULN (unless considered due to Gilbert's syndrome or hemolysis)
-
Willingness to undergo baseline and follow up biopsy to obtain tissue for DLL3 IHC and genomic analyses
-
In order to proceed with the treatment with 177Lu-DTPA-SC16.56, patients must exhibit overexpression of DLL3, as SUVmax greater than in normal liver, in ≥80% of tumor lesions among the growing progressing lesions that are ≥2cm.
Exclusion Criteria:
- History of anaphylactic reaction to humanized or human antibodies
- History of severe allergic reaction to X-ray contrast medium despite premedication
- Prior treatment with Rova-T (rovalpituzumab)
- Women who are pregnant or unwilling to discontinue breastfeeding
- Spinal cord compression or symptomatic/uncontrolled epidural disease, unless treated and stable for at least 1 week prior to enrolment.
- Males and females of reproductive potential who are unwilling to practice a highly effective method(s) of birth control while on study through 4 months for males and 7 months for females after receiving the therapeutic study drug. Acceptable methods of highly effective birth control include sexual abstinence (males, females); vasectomy; bilateral tubal ligation/occlusion; or a condom with spermicide (men) in combination with hormonal birth control or intrauterine device (IUD) (women)
- Life expectancy < 6 months as assessed by the treating physician.
- Unresolved toxicities from prior antitumor therapy, defined per Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, to to grade 1 or grade 0 or to levels dictated in the inclusion criteria.
- Major surgery within 28 days of enrolment with the exception of biopsy and insertion of central venous catheter.
- Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Known parenchymal brain metastases and/or carcinomatous meningitis, unless these metastases have been treated and stabilized.
- Unmanageable urinary incontinence rendering the administration of 177Lu-DTPA-SC16.56 unsafe (e.g., urinary catheterization not feasible).
- Other ongoing invasive malignances (i.e., not carcinomas in situ, non-mm invasive urothelial cancer, or other non-invasive tumors), and prior cancers that have been treated that have a >30% likelihood of relapse within the next two years.
- Subjects likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject's and investigator's knowledge.
- Prostate cancer patients with mixed histologies (i.e., neuroendocrine and adenocarcinomas) are eligible provided that they meet all of the above eligibility criteria.
- Patients for whom their clinicians believe would benefit by continuing their treatments for their disease to control any adenocarcinoma (such as ADT or other AR axis directed therapy) can and should remain on those treatments while on this protocol, if their clinician believes that it would be clinically beneficial to do so.
- Concurrent chemotherapy, other radiopharmaceuticals of any type, and immunotherapy are excluded
- Complementary approaches known to modulate PSA should not be taken while on this trial
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: 폐의 신경 내분비 암종 참가자
|
Participants will undergo 89Zr-DFO-SC16.56 Ab PET/CT 177Lu-DTPA-SC16.56, to be administered within 2 weeks of the PET/CT |
|
실험적: 신경 내분비 전립선 암 참가자
|
Participants will undergo 89Zr-DFO-SC16.56 Ab PET/CT 177Lu-DTPA-SC16.56, to be administered within 2 weeks of the PET/CT |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Maximum tolerated dose of 177Lu-DTPA-SC16.56
기간: Up to 36 months
|
Evaluating the safety and defining the MTD of 177Lu-DTPA-SC16.56 radiopharmaceutical therapy (RPT). |
Up to 36 months
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Lisa Bodei, MD, PhD, Memorial Sloan Kettering Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 24-330
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .